Clients

OncoSec Medical Inc.

Company Snapshot: OncoSec Medical Inc.

ONCS
Last Change Volume High Low

Company Overview

OncoSec Medical Inc. is a biopharmaceutical company developing its advanced-stage ImmunoPulse immunotherapy to treat solid tumors. OncoSec Medical's core technology leverages a proprietary electroporation platform to enhance the local delivery and uptake of IL-12 and other DNA-based immunocytokines. Clinical studies of ImmunoPulse have demonstrated positive safety and preliminary efficacy in the treatment of various skin cancers, as well as its potential to initiate a systemic immune response without the toxicities associated with other systemic treatments. OncoSec's clinical programs currently include three Phase 2 clinical trials targeting metastatic melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma. As the company continues to evaluate ImmunoPulse in these indications, it is also investigating additional indications as well as efficacious combination approaches.

Client News

  1. Mar 13 2019 OncoSec to Present at the 31st Annual ROTH Conference
  2. Feb 28 2019 OncoSec Announces Poster Presentation at 2019 American Association for Cancer Research Annual Meeting
  3. Feb 8 2019 OncoSec To Present At BIO CEO & Investor Conference
  4. Feb 1 2019 OncoSec Provides KEYNOTE-695 Clinical Update And Outlines 2019 Milestones
  5. Jan 22 2019 OncoSec to Host 2019 Business Outlook Conference Call on February 1, 2019